Neuralace Axon Therapy = Gamechanger?

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

drusso

Full Member
Moderator Emeritus
Lifetime Donor
Joined
Nov 21, 1998
Messages
13,305
Reaction score
7,969
Points
8,231
Location
Over the rainbow
  1. Attending Physician
Came back from the inaugural Pain Certification from Clinical TMS in June of this year. Both brain and peripheral neuromodulation research was reviewed, as well as the international speakers experience with these techniques. These techniques work on carefully selected patients. I find them to be infinitely (ok that might be an exaggeration) preferable to implanted devices. I think there are a plethora of new techniques that really move the needle (or perhaps remove the needle) in the management of chronic pain syndromes. Unfortunately, most of them are not reimbursed and therefore just not really trialed in most pain practices. And honestly, in most fast moving clinical practices, we hardly have enough time to pee, let alone learn new emerging techniques. Let us be both skeptical and curious.
 
Nothing is covered and it’s only getting worse. Makes it hard to learn new techniques. Which is of course what insurance prefers.
 
If this device is really only 9600 bucks seems like you could charge reasonable cash prices and get your money back pretty quick
 
Does anybody have real world experience with this? Desensitization is a really good modality for nerve pain but it’s hard to get people to do it.
 
Came back from the inaugural Pain Certification from Clinical TMS in June of this year. Both brain and peripheral neuromodulation research was reviewed, as well as the international speakers experience with these techniques. These techniques work on carefully selected patients. I find them to be infinitely (ok that might be an exaggeration) preferable to implanted devices. I think there are a plethora of new techniques that really move the needle (or perhaps remove the needle) in the management of chronic pain syndromes. Unfortunately, most of them are not reimbursed and therefore just not really trialed in most pain practices. And honestly, in most fast moving clinical practices, we hardly have enough time to pee, let alone learn new emerging techniques. Let us be both skeptical and curious.
So not at all.
 
Sesame Street Popcorn GIF by Muppet Wiki

Me waiting to see Ducttape’s take on the study design
 
i bet mille loves it
 
So obviously not blinded.

Wanted 90 ppl. Ended up with what 31 participants. That's a 1/3 of initial.

Fully 1/3 of treatment patients early terminated. 3 lost to follow up. Out of 31, only 16 or 1/2 of treatment group didn't complete.

The crossover group faired better. 13 of 19 completed.

So a study where there is visible active non blinded treatment did better than conservative treatment in patients with longstanding disease.



Definitely needs much more study.
 

We have treated one patient. It worked pretty well if I recall.

I don't like how the company is managing things. I would like to try it on more patients but logistically, the company makes it very difficult.
 
Must have witch hazel and eye of newt in your medicine cabinet. wont work otherwise.

I'm studying for my boards right now and this legit feels like a question on CAM. I just got a question wrong where I picked ginko, but the correct answer was feverfew. I understand that patients take these things, but I also freely admit that I threw my hands up in resignation and audibly exclaimed "who the f*** cares?" as I picked the wrong herb.
 
I think I read 9600 in the article posted, could be wrong though
 
Top Bottom